

## Metadata of the chapter that will be visualized online

Chapter Title	Design and Cloning of Short HairpinRNAs (shRNAs) into a Lentiviral Silencing Vector to Study the Function of Selected Proteins in Neuronal Apoptosis	
Copyright Year	2015	
Copyright Holder	Springer Science+Business Media New York	
Corresponding Author	Family Name	<b>Canu</b>
	Particle	
	Given Name	<b>Nadia</b>
	Suffix	
	Division	Department of System Medicine
	Organization	University of “Tor Vergata” Rome
	Address	Via Montpellier 1, Rome, 00137, Italy
	Email	cnanda00@uniroma2.it
Abstract	Double-stranded RNA-mediated interference (RNAi) is a new simple and fast research tool for shutting down genes and characterizes function of their respective proteins. Many strategies for design and delivery of siRNA to target cells are available. Here, we describe the use of lentiviral short hairpinRNA (shRNA) RNA silencing to identify the involvement of D-serineracemase (SR)- an enzyme that synthesizes D-serine modulate glutamate- <i>N</i> -methyl-D-aspartate receptor- in regulating ratcerebellar granule neurons (CGN) apoptosis. Apoptosis is induced by serum and KCl withdrawal and is detected with fluorometric caspase 3assay.	
Keywords (separated by “-”)	siRNA - ShRNA - Lentivirus - Cerebellar granule cells - D-serine racemase	

## Design and Cloning of Short Hairpin RNAs (shRNAs) into a Lentiviral Silencing Vector to Study the Function of Selected Proteins in Neuronal Apoptosis 2 3 4

[AU1] Nadia Canu 5

### Abstract 6

Double-stranded RNA-mediated interference (RNAi) is a new simple and fast research tool for shutting down genes and characterizes function of their respective proteins. Many strategies for design and delivery of siRNA to target cells are available. Here, we describe the use of lentiviral short hairpin RNA (shRNA) RNA silencing to identify the involvement of D-serine racemase (SR)- an enzyme that synthesizes D-serine to modulate glutamate- *N*-methyl-D-aspartate receptor- in regulating rat cerebellar granule neurons (CGN) apoptosis. Apoptosis is induced by serum and KCl withdrawal and is detected with fluorometric caspase 3 assay. 7  
8  
9  
10  
11  
12

**Key words** siRNA, ShRNA, Lentivirus, Cerebellar granule cells, D-serine racemase 13

---

## 1 Introduction 14

Gene knockout is used to study the function of specific gene, detect its protein product, and link it to physiological or pathological processes. Knockout can be deliberately made using different molecular techniques some of which, like homologous recombination, are lengthy and expensive. RNA interference (RNAi) has appeared as a novel pathway to knockdown specific mRNAs, thus preventing translation of the respective protein from occurring. 15  
16  
17  
18  
19  
20  
21

RNAi is a natural process—used in many different organisms to regulate endogenous gene expression—in which non-translated, long, double-stranded RNA (dsRNA) led to a strong, long lasting and specific silencing of selected genes [1]. Further studies revealed that small dsRNA of 21–25 bp (small interfering RNA = siRNA) derived from endonuclease Dicer-mediated processing of long dsRNAs interact with a protein complex to form the RNA-induced silencing complex (RISC) [2, 3]. This complex has nuclease activity and digests mRNA containing a base pair sequence identical to that in the siRNA. Thus, the siRNA serves 22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 as a target sequence that allows RISC to recognize specific  
33 mRNAs and to prevent their translation by cleaving them [4].  
34 Another method to produce siRNA is based on the use of short  
35 hairpin RNAs (ShRNAs) that trigger RNAi [5, 6]. Short (60–  
36 75 bp long) DNA oligodesoxynucleotides that form hairpins are  
37 cloned into a plasmid under the control of the U6 or H1 pro-  
38 moter for RNA polymerase III. Transfection of such a plasmid  
39 promotes the expression of ShRNAs that induce RNAi. Non-  
40 replicating recombinant viral vectors (adeno, adeno-associated  
41 and lentiviruses) are commonly used for ShRNA expression in  
42 primary neuronal cells. Lentiviruses may be particularly suited for  
43 long-term ShRNA and expression and gene silencing *in vivo* since  
44 the viral DNA gets incorporated in the host genome.

45 Commonly used lentiviral vector systems belong to the  
46 second or third generation, ensuring safe application, as these  
47 viruses are unable to self-replicate, since the spontaneous self-  
48 assembly is prevented by distributing the least necessary num-  
49 ber of virus elements on three and four plasmids, respectively.  
50 Here, we describe the methods used in our laboratory to silenc-  
51 ing SR in rat CGNs as a tool for identifying the role of this  
52 enzyme during apoptosis.

---

## 53 2 Materials

### 54 2.1 Design, 55 Production, 56 and Cloning of shRNAs 57 and Preparation 58 of Lentiviral Vectors

- 59 1. Packaging cell line: HEK (human embryonic kidney)-293T  
60 (Invitrogen™—Life Technologies™, Gaithersburg, MD). *See*  
61 **Note 1**.
- 62 2. 15 cm plates (Becton Dickinson Labware, Franklin Lakes, NJ).
- 63 3. Dulbecco's modified Eagle's medium (DMEM, Gibco™—  
64 Life Technologies™) with 2 and 10 % fetal bovine serum  
65 (FBS). *See Note 2*.
- 66 4. Lipofectamine 2000 (Invitrogen™—Life Technologies™).
- 67 5. Opti-MEM 1× (Gibco™—Life Technologies™).
- 68 6. Plasmids: pLVTHM; pCMVdR8.74; pMD2G (available from  
69 Addgene: <http://www.addgene.org/>) for second lentivirus gen-  
70 eration. For third lentivirus generation, refer to Dull et al. [7].
- 71 7. 10× Tris-buffered EDTA buffer (TBE buffer): 1 M Tris, 0.9 M  
72 boric acid, 0.01 M EDTA.
- 73 8. Extraction Kit (DNA 70–10 kb): e.g., QIAquick Gel 8  
74 (Quiagen GmbH, Hamburg, Germany).
9. Endotoxin-free plasmid maxipreps columns (Quiagen).
10. Tris-EDTA buffer (TE buffer 1×): 10 mM Tris, 1 mM EDTA,  
pH 8.0 with HCl.
11. Primer, 5' forward must contain an Mlu I site; Primer, 3'  
reverse must contain a Cla I site.

- |   |  |                                  |
|---|--|----------------------------------|
| 12.   | Restriction endonucleases: Mlu I, Cla I (New England Biolabs, Ipswich, MA).  | 75<br>76                         |
| 13.   | T4 DNA ligase 400,000 U/mL (New England Biolabs).  | 77                               |
| 14.   | 10× T4 DNA ligase buffer: 50 mM Tris-HCl, 10 mM MgCl <sub>2</sub> , 1 mM ATP, 10 mM DTT, pH 7.5.   | 78<br>79                         |
| 15.   | Bacterial growth strain(s): DH5α for pMD2G and pCMVdR8; HB101 for pLVTHM lentiviral vector. <i>See Note 3.</i>   | 80<br>81                         |
| 16.   | LB agar ampicillin plates: Use a 2 L flask to prepare 1 L of LB broth with agar (Lennox) (Sigma Chemicals, St. Louis, MO). To 1 L of distilled water add 35 g of LB agar. Swirl to dissolve and autoclave for 15 min at 120 °C to sterilize. Cool medium to 50 °C, and add 50–100 µg/mL ampicillin. Pour into Petri dishes and allow to solidify, store at 4 °C. | 82<br>83<br>84<br>85<br>86<br>87 |
| 17.   | Hank's Buffered Salt Solution (HBSS): 0.137 M NaCl, 5.4 mM KCl, 0.25 mM Na <sub>2</sub> HPO <sub>4</sub> , 0.1 g glucose, 0.44 mM KH <sub>2</sub> PO <sub>4</sub> , 1.3 mM CaCl <sub>2</sub> , 1.0 mM MgSO <sub>4</sub> , 4.2 mM NaHCO <sub>3</sub> .  | 88<br>89<br>90                   |
| 18.   | 20 % [w/v] sucrose in HBSS.  | 91                               |
| <b>2.2 Primary Cerebellar Granule Neuron Culture, Induction, and Detection of Apoptosis</b> |  |                                  |
| 1.  | Basal medium Eagle (BME; Life Technologies™).  | 92                               |
| 2.  | Bovine serum albumin (BSA, Sigma Chemicals).   | 93                               |
| 3.  | Krebs-Ringer bicarbonate medium (KRB): 120 mM NaCl, 5 mM KCl, 1.22 mM KH <sub>2</sub> PO <sub>4</sub> , 25.5 mM, 14 mM glucose, 4.2 mM phenol red.   | 94<br>95<br>96                   |
| 4.  | Solution A: KRB supplemented with 1.2 mM MgSO <sub>4</sub> , 3 mg/mL BSA.  | 97<br>98                         |
| 5.  | DNase I (Sigma Chemicals).   | 99                               |
| 6.  | Soybean trypsin inhibitor (Sigma Chemicals).   | 100                              |
| 7.  | Trypsin type III (Sigma Chemicals).  | 101                              |
| 8.  | L-Glutamine.   | 102                              |
| 9.  | Gentamicin sulfate.  | 103                              |
| 10.   | Fetal bovine serum (FBS, Gibco™).  | 104                              |
| 11.   | CGN culture medium: BME, 10 % FBS, 25 mM KCl, 2 mM glutamine, 100 mM gentamicin sulfate.   | 105<br>106                       |
| 12.   | 1β-Arabinofuranosylcytosine (Sigma Chemicals).   | 107                              |
| 13.   | Caspase 3 substrate: Ac-DEVD-AMC [ <i>N</i> -Acetyl-Asp-Glu-Val-Asp-AMC (7-amino-4-methyl coumarin)] (Biomol International, Plymouth Meeting, PA).   | 108<br>109<br>110                |
| 14.   | Caspase 3 lysis buffer A: 10 mM HEPES, pH 7.4, 42 mM KCl, 5 mM MgCl <sub>2</sub> , 1 mM , 1 mM PMSE, 0.5 % 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS), 1 µg/mL leupeptin.   | 111<br>112<br>113<br>114         |
| 15.   | Caspase 3 assay buffer B: 25 mM HEPES, 1 mM EDTA, 0.1 % CHAPS, 10 % sucrose, 3 mM DTT, pH 7.5.   | 115<br>116                       |

117 **2.3 Western Blotting**  
118 **and Immuno-**  
119 **fluorescence**  
120 **for D-Serine Racemase**

1. Lysis buffer: 25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate, 0.1 % SDS.
2. 10 % SDS-PAGE (Sodium Dodecyl Sulfate—PolyAcrylamide Gel Electrophoresis)- Laemmli protocol:
  - (a) 10 % lower gel (resolving gel): 4.9 mL distilled H<sub>2</sub>O, 2.5 mL 40 % acrylamide/Bis-acrylamide (29:1), 2.5 mL 1.5 M Tris, pH 8.8, 50  $\mu$ L 20 % SDS, 50  $\mu$ L 10 % ammonium persulfate, 10  $\mu$ L TEMED (total volume = 10 mL). Mix well and quickly transfer the gel solution by using 1 mL pipette to the casting chamber between the glass plates. Once the gel has polymerized, prepare stacking gel.
  - (b) 3.75 % stacking gel: 2.44 mL distilled H<sub>2</sub>O, 0.46 mL 40 % acrylamide/Bis- acrylamide (29:1), 1 mL 0.5 M Tris, pH 6.8, 40  $\mu$ L 10 % SDS, 15  $\mu$ L 10 % ammonium persulfate. Righ before pouring the gel add 1.5  $\mu$ L TEMED.
3. Agarose gel: agarose 1 % in TBE buffer 0.5 $\times$ .
4. Phosphate-buffered saline 1 $\times$  (PBS): 137 mM NaCl, 2.7 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.8 mM KH<sub>2</sub>PO<sub>4</sub>.
5. Normal goat serum (NGS) (Jackson ImmunoResearch, Europe Ltd., Newmarket, UK).
6. 100 % methanol.
7. Antifade mounting medium (ProLong<sup>®</sup> Gold Antifade—Life Technologies).
8. Mouse D-serine racemase antibody (BD Transduction laboratories<sup>™</sup>, San Jose, CA).
9. Affinity purified-goat D-serine racemase antibody (Santa Cruz Biotechnology, Dallas, TX).
10. Secondary TRITC-conjugated donkey anti-goat antibody (Jackson ImmunoReseach Europe Ltd.).

146 **2.4 Equipment**

1. Centrifuge (e.g., Beckman Coulter Inc, Brea, CA).
2. Tissue culture 15 cm dishes.
3. Tissue culture 6-well dishes.
4. Tissue-culture 24-well dishes for CGNs (Nunc A/s, Roskilde, Denmark).
5. Filters (0.22- or 0.45- $\mu$ m).
6. Incubators preset to 37 °C (5 % CO<sub>2</sub>).
7. Microcentrifuge.
8. PCR thermocycler.
9. SW 28 and SW 55 rotors (Beckman Coulter).
10. Sterile round-bottom polypropylene tubes 5 mL (e.g., BD Falcon, BD Biosciences, San Jose, CA).

11. 50 mL tubes.	158
12. Centrifuge, polyallomer, 5 mL tubes (Beckman Coulter).	159
13. Centrifuge, polyallomer, 12 mL tubes (Beckman Coulter).	160
14. Microcentrifuge tubes.	161
15. Vortexer.	162
16. 96-Well plate fluorescence reader (EnVision, PerkinElmer, Wellesley, MA).	163 164
17. Spectrofluorometer (e.g., Kontron AG, Zurich, Switzerland).	165
18. Protein electrophoresis/Western blotting apparatus.	166
19. Acrylamide gel electrophoresis apparatus.	167
20. Fluorescence microscope.	168

---

### 3 Methods

169

#### 3.1 Design, Production, and Cloning of shRNAs and Preparation of Lentiviral Vectors

ShRNA oligonucleotide design describes the process of identifying target sequences within a gene of interest and designing the corresponding oligonucleotides to generate the ShRNA.

170  
171  
172

##### 3.1.1 Design of shRNAs

A number of algorithms may be utilized to predict effective siRNA sequences and design ShRNA (e.g., <http://www.ambion.com/> or <http://sfold.wadsworth.org/>; <http://eu.idtdna.com/Scitools/Applications/shRNA> etc). Here are general guidelines for ShRNA design based on the work of Tuschl et al. [8] and Elabishir et al. [9, 10] (see also: <http://www.mpibpc.gwdg.de/abteilungen/100/105/sirna.html>).

173  
174  
175  
176  
177  
178  
179

1. Select a region of 19 nt within the gene to be silenced [in our case, rat D-serine racemase (NCBI accession number NM\_198757)] do not opt for region near the start codon (within 50-100 bases), nor untranslated regions [9, 10]. See Note 4.
2. Sequences that have at least 3 A or T residues in positions 15–19 of the sense sequence appear to have increased knock-down activity. See Note 5.
3. Ensure the content of GC of the 19 bases oligonucleotide between 40 and 60 %, and a GC content of approximately 45 % is ideal.
4. Examine the 19 bases oligonucleotide for secondary structure and long base runs, both of which can interfere with the process of annealing.
5. Filter out, by appropriate database search, candidate targets that are present in other genes to avoid silencing of these loci. See Note 6.
6. Add the 7–9 nt hairpin loop sequence between sense and anti-sense strand [11–14]. One of the most effective loop sequences for H1 promoter is TTCAAGAGA [15].

180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199

Nadia Canu

**a**

446  
GCGCAATCTCTTCTTCAA

597  
GCTCTCACCTATGCTGCTA

772  
GCATCTTGGTCCATCCAA

888  
GGAGGAATGGTTGCTGGAA

**b**

5' -cgcgTGCgCAATCTCTTCTTCAAATTCaAGAGATTGAAGAAGAGATTGCGCTTTTTat-----3'  
5' -cgatAAAAAGCGCAATCTCTTCTTCAAATCTCTTGAATTGAAGAAGAGATTGCGCa-----3'

and the annealed oligos are:

5' -cgcgTGCgCAATCTCTTCTTCAAATTCaAGAGATTGAAGAAGAGATTGCGCTTTTTat-----3'  
3' -----aCGCGTTAGAGAAGAAGTTTAAgTtCTCTAAACTTCTTCTTCTAACGCGAAAAAtagc-5'

**Fig. 1 (a)** Potential RNAi target sequences identified in the rat SR-coding region. **(b)** For one of the chosen sequences (GCGCAATCTCTTCTTCAA) the complementary oligonucleotide pair for the hairpin siRNA and the annealed oligonucleotides are reported. The TTCAAGAGA loop sequence is highlighted in *yellow*, the stretch T is highlighted in *light blue* and the restriction sites (MLu I and Cla I) in red lowercase

- 199 7. Place a stretch of 5–6 T at the end of ShRNA to guarantee the
- 200 termination of RNA polymerase III transcription.
- 201 8. Add to the end of two complementary oligonucleotides restric-
- 202 tion sites (in our case MLu I at 5' and Cla I at 3') (*see Fig. 1*).
- 203 9. Include a negative control ShRNA. Usually ShRNA design
- 204 online tools returns a scrambled sequence with the same nucle-
- 205 otide composition as your siRNA/shRNA input sequence.
- 206 10. Sense and antisense oligos must be phosphorylated and PAGE
- 207 purified in order to increase cloning efficiency. When order-
- 208 ing, be sure to require that oligonucleotides are supplied after
- 209 PAGE purification.

210 **3.1.2 Annealing**  
211 *of shRNA Oligonucleotides*

For expedience, annealing can be done in a thermal cyler.

- 212 1. Resuspend each PAGE-purified oligonucleotide in TE buffer
- 213 to a concentration of 100 μM.
- 214 2. Mix the oligos for the sense strand and the anti strand at a 1:1
- 215 ratio. This will ultimately give 50 μM of ds oligonucleotide
- 216 (assuming 100 % theoretical annealing).
- 217 3. Heat the mixture to 95 °C for 30 s. *See Note 7*.
- 218 4. Heat at 72 °C for 2 min.
- 219 5. Heat at 37 °C for 2 min.
- 220 6. Heat at 25 °C for 2 min.
7. Store on ice or at -20 °C until use.

3.1.3 Cloning ShRNA  
Oligonucleotides into  
pLVTHM

1. Dilute the annealed oligonucleotides with TE buffer to obtain a concentration of 0.5  $\mu\text{M}$ . 221  
222
2. For each ligation, add the following reagents in a microfuge tube: 223
  - 2  $\mu\text{L}$  digested (MLu I/Cla I) and dephosphorylated pLVTHM vector (100 ng/ $\mu\text{L}$ ). 224  
225
  - 4  $\mu\text{L}$  diluted, annealed oligonucleotide (0.5  $\mu\text{M}$ ). 226
  - 2  $\mu\text{L}$  10 $\times$  T4 DNA ligase buffer. 227
  - 0.5  $\mu\text{L}$  BSA (10 mg/mL). 228
  - 11  $\mu\text{L}$  Nuclease-free H<sub>2</sub>O. 229
  - 0.5  $\mu\text{L}$  T4 DNA ligase (400 U/ $\mu\text{L}$ ). 230
  - For a 20  $\mu\text{L}$  total volume. 231
3. Set up separate ligation using 2  $\mu\text{L}$  of the negative scramble control ShRNA annealed oligonucleotide. 232  
233
4. Set up separate ligation using 2  $\mu\text{L}$  of digested (MLu I/Cla I) pLVTHM vector (50 ng/ $\mu\text{L}$ ) without annealed oligonucleotide. 234  
235
5. Incubate ligation mixture at room temperature for 3 h. *See Note 8.* 236  
237
6. Transform immediately competent bacteria (with high transformation efficiency) and select on ampicillin plates. 238  
239
7. Digest plasmid DNA from colonies with MLu I/Cla I and run on a 12 % DNA polyacrylamide gel in TBE 1 $\times$  buffer gel (*See Note 9*). Positive clones will contain an approximately 60-bp insert compared to 17 bp for colonies without an insert. 240  
241  
242  
243
8. Sequence the insert with human H1 primer (TCGNTATGTG TTCTGGGAAA) to check hairpin integrity. 244  
245
9. Validate, by Western blot analysis or indirect immunofluorescence, the cloned ShRNA cassettes by transfecting pLVTHM-ShRNA as well as scramble vector in cell line that coexpresses the target gene. In our case, the cDNA for D-serine racemase together with ShRNA silencing cassette were transfected in an highly transfectable cell line (e.g., HEK-293). *See Note 10.* 246  
247  
248  
249  
250  
251

3.1.4 Preparation  
of Lentiviral Vectors

- You need to observe Biosafety-level-2 since application of this protocol leads to the production of pseudoviral particles capable of infecting mammalian cells. 252  
253  
254
1. For a 10 cm dish lentiviral preparation: plate lentivirus HEK-293-T cells at a density of approximately 100 cells/ $\text{mm}^2$  in 10 mL of DMEM, supplemented with 10 % FBS, 12–24 h before transfection. Addition of antibiotic solution does not interfere with transfection. 255  
256  
257  
258  
259
  2. To increase cell adherence, precoat twelve 15 cm dishes with 10 mL of poly-L-lysine, incubate for 30 min at room temperature 260  
261



- 262 under UV, and aspirate off the liquid. Grow the cells  
263 overnight at 37 °C in 5 % CO<sub>2</sub>. *See Note 11.*
- 264 3. Aliquot in 200 µL of Opti-MEM the three plasmids into a  
265 sterile polypropylene tube. For a 10 cm dish, use:
- 266 • -10 µg of lentivector pLVTHM.
  - 267 • -3.5 µg of pMD2G (Gag-Pol).
  - 268 • -6.5 µg of pCMVdR8.74.
- 269 4. In a separate tube, dilute 20 µL lipofectamine 2000 in 200 µL  
270 of Opti-MEM 1×.
- 271 5. Add diluted lipofectamine reagent drop-wise to the DNA  
272 solution while gently vortexing the DNA-containing tube and  
273 incubate for 30 min at room temperature. *See Note 12.*
- 274 6. Remove medium from cell plate, wash cells twice with Opti-MEM  
275 and add 5 mL of Opti-MEM without antibiotics. *See Note 13.*
- 276 7. Add the transfection mixture to each plate. Swirl the plates  
277 gently to distribute the complex and incubate overnight at  
278 37 °C in a 5 % CO<sub>2</sub> atmosphere.
- 279 8. Approximately 6–8 h after transfection, remove media. Add  
280 15 mL of fresh DMEM plus 2 % heat-inactivated FBS and  
281 penicillin-streptomycin to each plate and incubate overnight  
282 at 37 °C in a 5 % CO<sub>2</sub> atmosphere. *See Note 14.*
- 283 9. Collect the supernatant from the plates and centrifuge at  
284 500×g for 10 min to remove cell debris and filter through  
285 0.45 µm filters. *See Note 15.*
- 286 10. Add 15 mL of fresh medium to each plate and incubate over-  
287 night. Filtered supernatants can be stored for several days at 4 °C.
- 288 11. Collect media and filter as in **step 9**. *See Note 16.*
- 289 12. Pool collected supernatants from steps 9 and 11. Transfer to  
290 Beckman tubes using 25–29 mL per tube.
- 291 13. Concentrate viral particles by centrifuging in a Beckman SW  
292 28 rotor at 65,000×g or 2 h at 20 °C.
- 293 14. Resuspend all pellets in a total of 1 mL of HBSS and wash  
294 tubes a second time with 1 mL of HBSS.
- 295 15. Increase the combined volume from 2 to 3 mL with HBSS  
296 and layer the resuspended pellets on 1.5 mL of a 20 % sucrose  
297 (in HBSS) cushion in Beckman tubes.
- 298 16. Centrifuge using a Beckman SW 55 rotor at 53,500×g for  
299 1.5 h at 20 °C.
- 300 17. Resuspend the pellet in 100 µL of HBSS containing 1 % BSA and  
301 wash the tube with an additional 100 µL of HBSS containing 1 %  
302 BSA. Shake the resuspended viral preparation on a low-speed  
303 vortexer for 15–30 min. Centrifuge for 10 s to remove debris.

	18. Aliquot the cleared viral solution and store at $-80^{\circ}\text{C}$ . It can be stored for many months. Avoid repeated freeze-thaw cycles.	304 305
	19. Titrate the viral preparations by biological titration using GFP, which is the marker contained in the lentivector. The fraction of GFP fluorescent cells can be counted by FACS (fluorescence activated cell sorting). GFP fluorescence may be also visualized under a fluorescence microscope. Usually 10–15 random fields of view are used to estimate the overall fraction of fluorescing cells in each well.	306 307 308 309 310 311 312
<b>3.2 Primary Cerebellar Granule Neuron Cultures and Lentivirus Transduction</b>	Cultures enriched in CGNs are obtained from dissociated cerebella of 8-day-old Wistar rats according to Levi et al. [16]. The preparation of CGN cultures is carried out at <i>Day 1</i> , transduction at <i>Day 2</i> , induction and detection of apoptosis at <i>Days 6–7</i> .	313 314 315 316
<b>3.2.1 Primary Cerebellar Granule Neuron Cultures</b>	1. Remove 4–5 cerebella from 8-day-old rats and slice them (0.4 mm thickness) with a mechanical tissue chopper.	317 318
	2. Suspend in 10 mL solution A, centrifuge for 15 s at $150\times g$ .	319
	3. Resuspend the tissue in 10 mL solution A containing $0.25\ \mu\text{g}/\text{mL}$ trypsin III and incubate at $37^{\circ}\text{C}$ for 15 min in a shaking water bath at rate of 125 rpm.	320 321 322
	4. Add to the suspension 10 mL solution A containing $12.8\ \mu\text{g}$ DNAase I and $83\ \mu\text{g}$ soybean trypsin inhibitor.	323 324
	5. Centrifuge immediately for 15 s at $150\times g$ .	325
	6. Resuspend the pellet in 2 mL of solution A containing $80\ \mu\text{g}$ DNAase I, $0.52\ \text{mg}$ soybean trypsin inhibitor and $2.7\ \text{mM}$ $\text{MgSO}_4$ . Triturate the tissue with a Pasteur pipette (25 strokes).	326 327 328
	7. Allow the suspension to stand for 15 min, aspirate carefully the upper 1.5 mL, readjust the volume to about 2 mL and dissociate as above. After allowing the suspension to stand for 15 min, take off the supernatant, leaving only 0.2 mL containing clumps and debris.	329 330 331 332 333
	8. Transfer the supernatant into 3 mL Solution A containing $0.1\ \text{mM}$ $\text{CaCl}_2$ . After about 10 min decant the supernatant, allow to stand for another 10 min and resuspend the pellet in CGN culture medium.	334 335 336 337
	9. Count the cell in suspension.	338
	10. Plate $4\times 10^5$ CGN per well in a NUNC 24-well plate in $800\ \mu\text{L}$ CGN culture medium. Incubate the cells at $37^{\circ}\text{C}$ with 5 % $\text{CO}_2$ .	339 340
	11. After 24 h add $10\ \mu\text{M}$ $1\beta$ -Arabinofuranosylcytosine to CGN culture medium to prevent proliferation of non-neuronal cells.	341 342
<b>3.2.2 Transduction of Primary Cerebellar Granule Neuron Cultures</b>	1. Transduce CGN cells with lentivirus. For each well, prepare $50\ \mu\text{L}$ of virus suspension diluted in CGN culture medium (See Note 17). To transduce CGN reduce the volume of the	343 344 345

346  
347  
348  
349  
350

medium to one-third; add the recombinant lentivirus at different dilutions. Allow the virus to adsorb for 1–2 h, then render back the medium to its original volume. Then cultivate neurons up to 6–7 days in vitro (DIV) when apoptosis will be induced (Fig. 1).

351 **3.3 Induction**  
352 **and Detection**  
353 **of Apoptosis**

354 **3.3.1 Induction**  
355 **of Apoptosis**  
356

Induction of apoptosis is carried out in serum-free medium at low (5 mM) KCl [17].


1. Wash cultures twice and maintain in serum-free low (5 mM) KCl CGN culture medium for 8 h.
2. Wash and maintain control cultures in serum-free CGN culture medium for 8 h.

357 **3.3.2 Detection**  
358 **of Apoptosis**  
359


Measure caspase 3 activity as follows:

1. Wash 500,000 CGNs with PBS once.
2. Add 100  $\mu$ L of caspase 3 lysis buffer A to lyse cells.
3. Combine 25  $\mu$ L of lysate with 75  $\mu$ L of caspase 3 assay buffer B containing 30  $\mu$ M Ac-DEVD-AMC.
4. Incubate for 20 min at room temperature.
5. Measure fluorescence at an excitation of 380 nm and an emission of 460 nm using a spectrofluorometer (Fig. 2).

360  
361  
362  
363  
364



**Fig. 2** In vitro CGNs (2 DIV) were induced either with Sh-RNA/scramble and Sh-RNA/SR lentivirus at MOI 40. At 6DIV they were induced to undergo apoptosis by serum and KCl deprivation (S-K5); control cells were maintained in serum-free medium supplemented with 25 mM KCl (S-K25). Eight hours after apoptosis induction neurons were lysed and assayed for DEVD-MCA cleavage. Fold-induction of caspase-3 activity is the mean ( $\pm$ SEM) of triplicate determinations from three independent experiments. Note that silencing of SR increases caspase-3 activity in CGNs undergoing apoptosis, suggesting that this enzyme has a protective role in survival of CGN (see ref. 17)



**Fig. 3** (a) In vitro CGNs (2 DIV = day in vitro) were transfected either with Sh-RNA/scramble and Sh-RNA/SR lentivirus at MOI indicated. At 6DIV lysates were processed for SDS-PAGE and Western blot for immunodetection of SR and  $\beta$ -actin as control of silencing efficiency and specificity. (b) Confocal microscope analysis of SR expression at 6 DIV (red) in Sh-RNA/scramble and Sh-RNA/SR transfected CGNs at 2DIV at MOI 40.

### 3.4 Western Blotting and Immunofluorescence for D-Serine Racemase

#### 3.4.1 Western Blotting

1. Extract total proteins by scraping cells in SDS-reducing sample buffer. 365
2. Boil for 5 min. 366
3. Perform western blot analysis with mouse anti-D-serine racemase antibody (see Fig. 3a). 367

#### 3.4.2 Immunofluorescence

1. Fix and permeabilize CGN cultured in the chamber slide with methanol 100 % for 20 min at  $-20^{\circ}\text{C}$ . 368
2. Block with 4 % NGS in PBS for 1 h at room temperature. 369
3. Incubate slides with affinity purified-goat anti-D-serine racemase antibody diluted 1:50 in PBS overnight at  $4^{\circ}\text{C}$ . 370
4. Wash three times with PBS. 371

- 376  
377  
378  
379  
380  
381  
382  
383
5. Add secondary TRITC-conjugated donkey anti-goat antibody diluted 1:200 in PBS and incubate at room temperature for 30 min in a humid chamber.
  6. Wash three times with PBS.
  7. Remove excess moisture from the slide before adding anti-fade mounting medium.
  8. Examine slide under fluorescence/confocal microscope (*see* Fig. 3b).

---

#### 384 4 Notes

- 385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416
1. Cells should be of low-passage number and should not be used after passage 20 or if growth is slow.
  2. Certain brands of FBS do not support efficient transfection and can result in low viral titers. We routinely use FBS, Qualified, Australia Origin from Gibco™.
  3. There is an additional Cla I site in pLVTHM vector that is blocked by Dam methylation. The plasmid needs to be grown in a Dam<sup>+</sup> bacterial strain such HB101 in order to use Cla I for cloning.
  4. Although it is recommended to avoid to select target sequence in the untranslated regions, since regulatory protein binding to regions in and near the untranslated region might interfere with the RNAi process, in some case targets within the untranslated regions (UTR) have been also reported [18].
  5. Avoid selecting target sense or antisense sequences that contain a consecutive run of three or more thymidine residues; a poly(T) tract within the sequence can potentially cause premature termination of the shRNA transcript.
  6. Many online tools to design shRNA gives a link to the NCBI BLAST server to search for similarity of the suggested target against the mRNA database of the organism of interest.
  7. Heating to 95 °C is essential to remove all secondary structure, disrupt the internal hairpin of each oligonucleotide and promote intermolecular annealing.
  8. If you are unable to perform immediately transformation, store ligation at -20 °C.
  9. See Tables 5 and 6 in Sambrook and Russell, Molecular Cloning 3rd Ed VIII, p5.42 for different acrylamide concentrations and the effective range of DNA fragment sizes separated.
  10. We have transfected 200 ng of target cDNA plasmid (HA-D-serine racemase) plus 500–1,000 ng of the plasmid containing the silencing cassette per 6-well plate and harvest the cells for immunoblot analysis 48–72 h after transfection.

11. For best result and to optimize viral titer cells must be at 417  
70–80 % confluence, equably distributed and with flat mor- 418  
phology before transfection. 419
12. The DNA-lipofectamine complex must be formed in the 420  
absence of proteins even though the complex is able to transfect 421  
cells in the presence of proteins such as 10 % FBS. Opti-MEM I 422  
is recommended for diluting both DNA and lipofectamine 423  
reagent. The ratio of 2.0  $\mu$ L of lipofectamine 2000 per 1  $\mu$ g of 424  
plasmid has been found to be optimal. Increasing the ratio does 425  
not further improve transfection efficiency. 426
13. Though the complex is able to transfect cells in the presence 427  
of proteins such as 10 % FBS, we found an improved transfec- 428  
tion efficiency in the absence of serum. 429
14. To increase the lentivirus titer we have added, caffeine to a final 430  
concentration of 2–4 mM for 17–40 h post-transfection [19]. 431
15. Do not use nitrocellulose filters, as nitrocellulose is known to 432  
bind lentivirus and reduce titers. Use 0.45  $\mu$ m polyethersul- 433  
fone (PES) low protein-binding filters. 434
16. Peak of virus production is normally achieved 24–48 h post- 435  
transfection; however collecting medium at multiple times at 436  
36, 48, and 60 h post-transfection increases the viral yield. 437
17. Use several multiplicity of infection (MOI) virus stock to find 438  
the more suitable MOI to obtain silencing of you gene of 439  
interest. In addition, include a transduction with the scramble 440  
control and other appropriate positive and negative controls. 441  
Mix the virus with the medium gently by inverting the tubes 442  
several times. Do not vortex. 443

---

## Acknowledgments

444

This work was supported by grants from Italian Ministry of Education, 445  
University and Research (PRIN 2009, 2009KP83CR-02 to NC). 446

## References

447




- 448 1. Fire A, Xu S, Montgomery MK, Kostas SA, 460  
449 Driver SE et al (1998) Potent and specific 461  
450 genetic interference by double-stranded RNA in 462  
451 *Caenorhabditis elegans*. *Nature* 391:806–811 463
- 452 2. Hannon GJ (2002) RNA interference. *Nature* 464  
453 418:244–251 465
- 454 3. Dykxhoorn DM, Novina CD, Sharp PA (2003) 466  
455 Killing the messenger: short RNAs that silence 467  
456 gene expression. *Nature* 4:457–467 468
- 457 4. Hammond SM (2005) Dicing and slicing the 469  
458 core machinery of the RNA interference path- 470  
459 way. *FEBS Lett* 579:5822–5829 471
5. Yu JY, DeRuiter SL, Turner DL (2002) RNA 460  
interference by expression of short-interfering 461  
RNAs and hairpin RNAs in mammalian cells. 462  
*Proc Natl Acad Sci U S A* 99:6047–6052 463
6. Paddison PJ, Caudy AA, Bernstein E, Hannon 464  
GJ, Conklin DS (2002) Short hairpin RNAs 465  
(shRNAs) induce sequence-specific silencing in 466  
mammalian cells. *Genes Devel* 16:948–958 467
7. Dull T, Zufferey R, Kelly M, Mandel RJ, 468  
Nguyen M et al (1998) *J Virol* 72:8463–8471 469
8. Tuschl T (2006) Selection of siRNA sequences 470  
for Mammalian RNAi. *CSH Protoc* 471

471 AU3]

- 472 9. Elbashir SM, Martinez J, Patkaniowska A, 495  
473 Lendeckel W, Tuschl T (2001) Functional 496  
474 anatomy of siRNAs for mediating efficient 497  
475 RNAi in *Drosophila melanogaster* embryo 498  
476 lysate. *EMBO J* 20:6877–6888 499
- 477 10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, 500  
478 Weber K et al (2001) Duplexes of 21-nucleotide 501  
479 RNAs mediate RNA interference in cultured 502  
480 mammalian cells. *Nature* 411:494–498 503
- 481 11. Vermeulen A, Behlen L, Reynolds A, Wolfson 504  
482 A, Marshall W et al (2005) The contributions 505  
483 of dsRNA structure to Dicer specificity and 506  
484 efficiency. *RNA* 11:674–682 507
- 485 12. Hannon GJ, Rossi JJ (2004) Unlocking the 508  
486 potential of the human genome with RNA 509  
487 interference. *Nature* 431:371–378 510
- 488 13. Gönczy P, Schnabel H, Kaletta T, Amores AD, 511  
489 Hyman T et al (1999) Dissection of cell divi- 512  
490 sion processes in the one cell stage 513  
491 *Caenorhabditis elegans* embryo by mutational 514  
492 analysis. *J Cell Biol* 144:927–946 515
- 493 14. Jantsch-Plunger V, Glotzer M (1999) 516  
494 Depletion of syntaxins in the early 517  
518 *Caenorhabditis elegans* embryo reveals a role 519  
519 for membrane fusion events in cytokinesis. 520  
520 *Curr Biol* 9:738–745 521
- 515 15. Brummelkamp TR, Bernards R, Agami R 498  
(2002) A system for stable expression of short 499  
interfering RNAs in mammalian cells. *Science* 500  
296:550–553 501
- 516 16. Levi G, Aloisi F, Ciotti MT, Gallo V (1984) 502  
Autoradiographic localization and depolarization- 503  
induced release of acidic aminoacids in differ- 504  
entiating cerebellar granule cultures. *Brain Res* 505  
290:77–86 506
- 517 17. Esposito S, Pristerà A, Maresca G, Cavallaro S, 507  
Felsani A et al (2012) Contribution of serine 508  
racemase/d-serine pathway to neuronal apop- 509  
tosis. *Aging Cell* 11:588–598 510
- 518 18. Anthony KG, Bai F, Krishnan MN, Fikrig E, 511  
Koski RA (2009) Effective siRNA targeting of 512  
the 3' untranslated region of the West Nile 513  
virus genome. *Antiviral Res* 82:166–168 514
- 519 19. Ellis BL, Potts PR, Porteus MH (2011) 515  
Creating higher titer lentivirus with caffeine. 516  
*Hum Gene Ther* 22:93–100 517

# Author Queries

Chapter No.: 9      0002217839

Queries	Details Required	Author's Response
AU1	Please check whether the affiliation is appropriate as typeset.	
AU2	Please check whether the term "Righ" can be changed to "Right".	
AU3	Please provide complete bibliographic details for Ref. [8].	

Uncorrected Proof